HOPA 2026 BCOP-Only Bundle On-Demand

UAN#: 0465-0000-26-006-H01-P

Presenter:

• Mary Walters, PharmD, BCOP - Director Pharmacy Precision Medicine

Session Description:

This program prepares oncology pharmacists to interpret tumor molecular profiling, emphasizing tumor-agnostic indications. Participants will learn a stepwise approach to recommending personalized therapies by analyzing test features, evaluating variant significance, and applying results to each patient's clinical context.

Learning Objectives:

1. Define the role of tumor agnostic therapies in Precision Oncology
2. Assess the characteristics of biomarker tests
3. Evaluate the clinical significance of a tumor agnostic biomarker
4. Contextualize tumor-agnostic biomarker results to individualized therapeutic plans

UAN#: 0465-0000-26-007-H01-P

Presenters:

• Benjamin Lee, PharmD, BCOP, BCPS - Clinical Pharmacy Specialist, Lymphoma/Myeloma/CART
• Brian Primeaux, PharmD, BCOP - Clinical Pharmacy Manager, Lymphoma/Myeloma/CART

Session Description:

There have been many changes in the management of newly-diagnosed and relapsed/refractory Hodgkin Lymphoma (HL). The addition of Nivolumab-AVD, Brentuximab vedotin (BV)-AVD, and BrECADD as preferred regimens and the introduction of PET-adapted treatment has changed the treatment landscape of newly-diagnosed Stage III-IV HL. For the relapsed/refractory setting, the addition of immune checkpoint inhibitors and antibody-drug conjugates have added additional treatment options for patients who would have otherwise received traditional chemotherapy (GVD or ICE alone).

This session will discuss pivotal trial data associated with novel combinations in all lines of therapy for HL and how to apply this data clinically to therapy selection for patients. Additionally, the implementation of PET-adapted therapy in late stage newly-diagnosed patients will be explored.

Learning Objectives:

1. Describe the clinical presentation and pathological features of classical Hodgkin Lymphoma (cHL)
2. Analyze pivotal clinical trial data for novel treatment strategies in newly-diagnosed, advanced stage cHL
3. Select the appropriate initial therapy for a patient with newly-diagnosed, advanced stage cHL
4. Design a therapy plan for a patient with newly-diagnosed, advanced stage cHL based on interim PET results
5. Evaluate clinical trial data on targeted agents in relapsed/refractory cHL

UAN#: 0465-0000-26-010-H05-P

Presenters:

• Nic Mastascusa, PharmD, BCNP - Associate Professor
• Kellie Weddle, PharmD, BCOP, FCCP, FHOPA - Clinical Professor

Session Description:

In this session, we will conduct a brief review of theranostics, including a brief discussion of currently available therapeutic radiopharmaceuticals. We will highlight specific issues related to the safe and effective use of these agents. A snapshot of drug development in this space will also be discussed. This will be followed by an interactive presentation of clinical examples of the use of theranostic agents, including discussions around introducing radiopharmaceuticals in the clinical care plan. We will evaluate the impact on patient clinical outcomes, how to identify, minimize, and treat adverse events related to these agents and assure safety to the patients, caregivers, and healthcare providers.

Learning Objectives:

1. Identify key concepts related to the use of radioactive materials for theranostic applications
2. Recall current FDA approved radiopharmaceuticals (RP) and provide an overview of the RP pipeline
3. Analyze case-based examples of patients eligible for RP therapy
4. Interpret patient specific parameters and evaluate patient outcomes when considering RP therapy
5. Illustrate ways to implement RP into clinical practice

UAN#: 0465-0000-26-028-H99-P

Presenters:

• Elyse MacDonald, PharmD, MS, BCPS, FASHP - Director of Pharmacy Services
• Jennifer Murphy, PharmD, BCOP - Senior Pharmacist in the Cancer Center Investigational Drug Service

Session Description:

This engaging and innovative session will lead the audience through a thought-provoking approach to evaluating their current research pharmacy practices and how to invite process improvement into their respective workplace and across the institutional enterprise. The speakers will highlight implementation strategies and best practices for start-up, life-cycle management, accountability, regulatory compliance, metrics, financial health/budgets, and technology along with a call to action for pharmacists to strengthen clinical trial conduct at their sites.

Learning Objectives:

1. Identify the common challenges faced in pharmacy operations during clinical trials
2. Apply best practices and innovative strategies that can enhance the efficiency of pharmacy operations in clinical trials
3. Develop strategies to effectively navigate and overcome challenges in implementing site efficiencies in clinical trials
4. Illustrate the role of the research pharmacy workforce to advocate for site workflows, growth, implementation, and challenges across the site/enterprise

UAN#: 0465-0000-26-030-H01-P

Presenters:

• Andrew Kowalski, PharmD, BCOP - Multiple Myeloma Clinical Pharmacist
• Jordan Snyder, PharmD, BCOP - Clinical Hematology Pharmacist

Session Description:

Quadruplet induction regimens, CAR-T cell therapies and bispecific antibodies are changing the treatment landscape of multiple myeloma from new diagnosis through late relapse. This BCOP session will address quadruplet induction therapy for newly diagnosed myeloma and the shifting role of autologous stem cell transplant in consolidation. Attendees will also gain valuable insight into the emergence of CAR-T in early relapse and the appropriate sequencing of bispecific antibodies, CAR-T, and many other options. Grab your ruby slippers because we're not in Kansas anymore.

Learning Objectives:

1. Describe the data supporting quadruplet therapy in transplant eligible and transplant ineligible newly diagnosed multiple myeloma
2. Evaluate the paradigm of autologous stem cell transplant for multiple myeloma in the context of newer therapeutic options
3. Compare the use of CAR-T to established combination therapies in the setting of early relapse in multiple myeloma
4. Examine the use of bispecific T-cell engagers in relapsed/refractory multiple myeloma
5. Create a treatment plan for a patient with relapsed/refractory multiple myeloma based on available data sequencing therapies

UAN#: 0465-0000-26-051-H01-P

Presenters:

• Emma Jones, PharmD, BCOP - Genitourinary Clinical Oncology Specialist
• Jordan McPherson, PharmD, BCOP, MS - Oncology Pharmacy Manager

Session Description:

This session will guide pharmacists through the evolving landscape of steroid-refractory immune-related adverse events (irAEs). Focusing on high-risk toxicities - colitis, pneumonitis, hepatitis, and myocarditis - experts will review pathophysiology, treatment escalation, and emerging therapies. This presentation will also briefly address management of less common irAEs. Attendees will explore current limited literature, consensus guideline updates, and ongoing clinical trials. Clinical cases will highlight logistical hurdles in initiating secondary immunosuppressants and coordinating subspecialty care. A blend of lecture and interactive discussion will provide practical insights to support early recognition, timely escalation, and optimal immunosuppressive selection for steroid-refractory irAEs.

Learning Objectives:

1. Review the fundamentals of steroid-refractory immune-related adverse event management
2. Describe the irAEs that commonly and uncommonly present as steroid-refractory
3. Identify agents utilized in the management of steroid-refractory irAEs
4. Evaluate notable recent literature on steroid-refractory irAE management
5. Apply principles of steroid-refractory irAE management to guide treatment in patient cases

UAN#: 0465-0000-26-053-H01-P

Presenters:

• Natalie Brumwell, PharmD, BCOP - Clinical Pharmacy Specialist
• Jamie Marchesseault (Brown), PharmD, BCOP - Clinical Pharmacy Specialist
• Mary McGann, PharmD, BCOP - Pharmacy Clinical Specialist

Session Description:

As the use of CAR-T cell therapy expands, clinicians are increasingly challenged by the unique and evolving infectious complications that follow treatment. This BCOP CE session will explore the pathophysiology, epidemiology, prevention, and management strategies for infections post-CAR T, with a focus on optimizing patient outcomes through evidence-based management and education.

Learning Objectives:

1. Describe the pathophysiologic mechanisms and immunologic changes that predispose patients to infections following CAR-T cell therapy
2. Review the incidence and timing for bacterial, viral, and funal infections in patients receiving CAR-T cell therapy
3. Develop individualized antimicrobial prophlaxis and infection monitoring strategies for patients receiving CAR-T cell therapy
4. Apply evidence-based approaches for managing infectious complications after CAR-T cell therapy
5. Evaluate vaccination strategies after CAR-T cell therapy